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Fish oil in lupus nephritis: Clinical findings and methodological impli-
cations. Our objective was to determine the effects of fish oil on renal
function, symptoms, and serum lipids in patients with lupus nephritis. A
double-blind, randomized crossover trial of fish oil versus placebo
(olive oil) was done on 26 patients with confirmed systemic lupus; 21
completed the study. Intervention was fish oil or placebo, 15 glday, for
one year followed by a 10 week wash-out period, and then the reverse
treatment for one year. At baseline and six month intervals, we
measured platelet membrane fatty acids, indices of renal function, a
disease activity index, serum lipid levels, blood pressure, serum vis-
cosity and red cell flexibility. We found that platelet membrane phos-
pholipids were uniformly affected by fish oil supplementation (P <
0.001) but with significant carry-over effects despite a 10 week wash-out
period. Glomerular filtration rate and serum creatinine were not af-
fected. A non-significant reduction in mean (SE) 24-hour proteinuria
occurred, from 1424.1 mg (442.7) on placebo to 896.7mg (352.2) on fish
oil (P = 0.21). Fish oil lowered serum triglycerides from 1.89 (0.25)
mmol/liter to 1.02 (0.11) mmol/liter (P = 0.004). VLDL cholesterol
decreased markedly whether patients initially received fish oil or
placebo (P = 0.004). The size of the reduction was affected by the order
of treatment (P = 0.03), but parallel comparisons were significant
before the crossover (P = 0.0006). With the possible exception of
bleeding time, no other treatment effects were shown with fish oil.
However, treatment order effects were seen in urinary IgG excretion (P
= 0.03), whole blood viscosity (P < 0.0001), red cell flexibility (P =
0.004), and bleeding time (P = 0.06). In conclusion, one year of dietary
supplementation with fish oil in patients with stable lupus nephritis did
not improve renal function or reduce disease activity, but did alter some
lipid parameters. Hitherto unreported carry-over effects and treatment
order effects caused by the olive oil created a risk of type 11 error, and
bear methodologic consideration in the design of future studies.
With improvements in long-term prognosis, patients with
systemic lupus erythematosus (SLE) now manifest a clinical
course of early inflammatory and late atherosclerotic vascular
events [1—9]. These observations have attracted our interest in
fish oil as a form of nutritional intervention in human systemic
lupus erythematosus. Fish oil and its principal constituents,
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
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possess both anti-inflammatory and anti-atherosclerotic proper-
ties [10]. Omega-3 fatty acids inhibit inflammatory pros-
taglandin and leukotriene production by displacing the arachi-
donic acid (AA) substrate from cell membranes and competing
with the AA for cyclooxygenase and lipoxygenase enzymes
[11—131. This competition results in a shift towards the produc-
tion of non-inflammatory series-3 prostaglandins and series-5
leukotrienes [12, 13]. Fish oil supplementation has been found
to induce clinical responses in inflammatory diseases including
rheumatoid arthritis, psoriasis and ulcerative colitis [14—18].
Fish oil supplementation has also been implicated in the lower-
ing of lipid levels and a reduction in atherosclerotic vascular
events in humans [19—24]. This dual action of fish oil has the
potential to alter the bimodal morbidity and mortality pattern
related to inflammatory and atherosclerotic events in patients
with lupus nephritis.
In three different experimental murine models of lupus
(NZB/W, BXSB, MRLI1PR) dietary fish oil reduces proteinuria
and renal morphologic injury [25—29]. In the NZB/W and the
BXSB mouse it also decreases mortality [25—27]. The anti-
inflammatory and anti-atherosclerotic potential of fish oil cou-
pled with the findings in the murine experiments prompted us to
test the effects of fish oil supplementation in patients with lupus
nephritis. Our previous dosing study of fish oil (MaxEPA) in
lupus nephritis patients indicated that both low (6 g/day) and
higher doses (18 glday) were well tolerated and inhibited
inflammatory mechanisms, but only the higher dose corrected
dyslipidemias [30]. We now report a prospective placebo-
controlled, single center, double-blind crossover study of the
effects of dietary fish oil supplementation on renal function,
dyslipidemia, clinical disease activity and immunologic markers
of inflammation in patients with lupus nephritis.
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Methods
Patients
The study was approved by the Review Board for Health
Sciences, University of Western Ontario. Forty-three patients
with the diagnosis of lupus nephritis attending nephrology
clinics at the University of Western Ontario were invited to
participate in the study. Twenty-six patients consented to
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Table 1. Patients completing 2 year + 10 week double-blind
cross-over study
Proteinuriab
Patient Sex Age AMA Renal biopsya mg/24 hr
Group 1: Fish oil 1st year
9 44 + DPGN 106
2 9 37 + No biopsy 190
3 9 49 + DPGN 461
4 9 22 + No biopsy 7456
5 9 47 + DPGN 55
6 2 55 + FPGN 1465
7 2 37 + No biopsy 148
8 53 ÷ DPGN 70
9 9 27 + DPGN 2501
10 9 35 + DPGN 1489
11 66 + DPGN 1910
12 9 35 + DPGN 1802
13 2 35 + FPGN 130
Group 2: Olive oil 1st year
1 2 30 + DPUN 451
2 2 37 + DPGN 630
3 9 30 + DPGN 133
4 2 38 + No biopsy 45
5 d 32 + No biopsy 43
6 9 38 + No biopsy 262
7 35 + DPGN 5596
8 9 28 + No biopsy 6541
Biopsy classification: DPGN, diffuse proliferative; FPGN, focal
proliferative.
b Proteinuria at the onset of the study
participate and 21 completed the study. The other five indicated
either a loss of interest or relocation as their reason for dropping
out. Thirteen of the 21 patients began the trial on fish oil
(hereafter Group 1) and completed it on placebo (olive oil
supplement). The remaining eight patients (Group 2) were given
the treatments in reverse order.
The characteristics of the patients in the two groups are
recorded in Table 1. The mean (SE) age of the study population
was 38.6 (2.3) years. All patients met a minimum of four of the
ARA criteria for the diagnosis of SLE and all were ANA
positive [31]. Nephritis associated with SLE was diagnosed by
the presence of proteinuria of  500 mg/24 hr, or an active
urinary sediment defined by the presence of one or more red
cell cast, or  10 red cells/high power field (400 x magnifica-
tion), 75% of which were dysmorphic. Fourteen patients had
undergone previous renal biopsy, 12 indicating diffuse prolifer-
ative glomerulonephritis and two indicating focal proliferative
glomerulonephntis (Table 1). At the onset of the study most
patients were in a stable condition with 13 showing proteinuria
of greater than 150 mg/24 hr, and 20 showing active urinary
sediments.
Trial design
The design was a standard double-blind, randomized cross-
over comparison, where fish oil (MaxEPA) was paired with
placebo (olive oil) [32]. After giving informed consent patients
were randomized to receive fish oil (Group 1) or placebo (Group
2) for one year. This was followed by a 10 week wash-out period
during which no capsules were provided. Patients then crossed
over to begin the second one year period of study on the other
dietary supplement. Patients were asked to take five fish oil or
placebo capsules three times per day. The 15 MaxEPA capsules
contained 2.7 grams of EPA and 1.7 grams of DHA. Both fish
oil and placebo capsules provided equal calories (157.5 Kcals).
Patients were asked to maintain their usual diet throughout the
study. Both patients and physicians were blinded to the treat-
ment status.
Medication
Patients receiving non-steroidal anti-inflammatory therapy or
cytotoxics received the same dose throughout the trial. Pred-
nisone dosages were adjusted by the attending physician (WFC)
who was blinded to the dietary supplementation period. Dosage
changes were based on clinical responses and/or biochemical
and serologic changes.
Measurements
At initiation and at six month intervals patients presented
after an overnight fast and underwent clinical, blood and urine
testing, including analysis of recent 24-hour urine collections
for protein estimation. Blood was withdrawn from the subjects
for determination of routine hematology, biochemistry and
immunology analysis as well as platelet membrane phospholip-
ids, serum lipids, whole blood viscosity, and red cell flexibility
measurements. A urinalysis was performed on fresh urine
collected at each visit. The patients also underwent a three-hour
Tc-DTPA GFR study at each visit. During the study period
subjects were assessed by the same physician, blinded to the
dietary supplementation, who scored the SLE Disease Activity
Index (SLEDAI) (Appendix 1) [33] and carried out blood
pressure determinations in a recumbent position with Korot-
koff's fifth sound as the diastolic blood pressure cut-off.
Patient compliance
This was assessed by capsule counts and by the platelet
membrane n-3 (including EPA and DHA) versus n-6 fatty acid
incorporation. Patients were given a surplus of capsules by the
study pharmacist. The pill count was performed by the blinded
research coordinator when patients returned at the six-month
study intervals and received a new six month supply of cap-
sules.
Platelet phospholipid fatty acid content
Platelets obtained from blood collected in EDTA, were
washed with a phosphate buffer saline (PBS; 120 mmol sodium
chloride, 10 mmol sodium phosphate and 13 mmol sodium
citrate, pH 6.8) and then resuspended in Hanks buffered salt
solution. One ml suspension (1 x io platelets) was used for
lipid extraction by a procedure modified from that of Bligh and
Dyer [34]. For this purpose, 3.5 ml methanol chloroform (2:1)
was added and the tube was vortexed for 60 seconds. Finally,
1.75 ml distilled water was added and vortexed for 15 seconds.
The tubes were then stored at —70°C until assayed [35].
Phospholipids from the lipid extracts were separated by thin-
layer chromatography using silica Gel H as the stationary phase
(Merck Co., Darmstadt, Germany) followed by development in
heptane:isopropyl ether:acetic acid (60:40:3, vollvollvol). The
bands corresponding to the different lipid fractions were
sprayed with a solution of 2,7-dichiorofluorescein (Sigma
Chemical Co., St. Louis, Missouri, USA) and visualized under
ultraviolet light. The phospholipid band was scraped from the
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plates, known amounts of monopentadecanoin (Nu-Check Prep
Inc., Elysian, Minnesota, USA) added as the internal standard
and samples transmethylated at 80°C with 6% H2504 in meth-
anol (vollvol). The resulting fatty acid methyl esters were
identified by a comparison of their retention times to those of
known fatty acid standards, using the Hewlett Packard, Model
5890A gas chromatograph, equipped with a DB225 megabore
column (Chromatographic Specialties, Brockville, Ontario,
Canada). The gas flow rates (ml/min) were 356 for air, 35 for
hydrogen and 31 for nitrogen, and the flame ionization detection
temperature was 250°C during these isothermal runs [36].
Renal function tests
Total urinary proteins were measured using sulfasalicylic
acid precipitation. Glomerular filtration rate (GFR) was deter-
mined by injecting Tc-DTPA and constructing clearance curves
based on three consecutive hourly blood samples [37]. Serum
creatinine was measured by kinetic Jaffè chromogen reaction
using Paramax Analytical System (Baxter, Irvine, California,
USA). Urinary IgG was measured in aliquots of 24-hour urine
collections by the ELISA technique using reagents from Nordic
Immunological Laboratories (Cedarlane Labs, Hornby, On-
tario, Canada).
Plasma lipid analysis
Plasma samples were obtained from blood collected in EDTA
on ice. Total plasma cholesterol and plasma triglyceride levels
were determined by enzymatic reagents obtained from Boeh-
ringer-Mannheim, Montreal, Quebec, Canada (cholesterol:
CHOD-PAP; triglycerides: without free glycerol). The HDL
cholesterol was determined enzymatically following precipita-
tion of plasma with dextran sulphate-magnesium chloride as
described by Warnick, Benderson and Albers [38]. VLDL and
LDL cholesterols were calculated as described by Freidewald,
Levy and Fredrickson [39].
Red cell flexibility
Heparinized blood was centrifuged for two minutes in a Clay
Adams Autocrit centrifuge (Clay Adams Co., Parsippany, New
Jersey, USA). Voltage supplied to the centrifuge was adjusted
with a Powerstat variable transformer (Speer Electric Co.,
Bristol, Connecticut, USA) to achieve 200 g. Red cell flexibility
(RCF) was measured as a percentage of cell packing/mm as
outlined by Sirs [40].
Whole blood viscosity (WBV)
The viscosity of heparinized whole blood relative to water
was measured using a white cell pipette at room temperature
according to the method of Wright and Jenkins [41].
Bleeding time
Bleeding time (expressed in minutes) was performed using
the Simplate II device (Organon Teknika Corp., Durham, North
Carolina, USA).
Immunology
Serum complement (C3 and C4) were measured by scattered
light turbidity in a nephelometer (BNA Nephelometer, Behring-
werke AG Diagnostica, Marburg, Germany). Antibodies to
double-stranded DNA antibodies (ds-DNA binding activity)
were measured in sera using the Fan ammonium sulphate
precipitation technique. The data were transformed for analysis
using the formula: (DNA value — 0.20)/(0.20 x 100), which was
necessitated because our Immunology Laboratory could not
measure levels below 0.20 (these are reported simply as <0.20).
Sample size
The planned sample size of 32 was based on feasibility and on
the previous dosing study which showed a 25% relative increase
in HDL levels over five weeks [30] and labeled it statistically
significant with a much smaller number of patients. Using the
observed means and standard deviations from baseline data in
this study, and assuming a 25% increase in HDL levels, a
two-tailed a of 0.05, and a p of0.80, the N needed per group in
a cross-over design was 13 [42]. Hence, before drop-outs, the
study was adequately powered to detect and label significant
the desired change in HDL. For other outcomes, no evidence-
based sample size predictions could be made since there were
no similar longitudinal or intervention studies in SLE.
Data analysis
Statistical analyses followed the suggestions of Armitage and
Berry [43] and Fleiss [44]. A randomized cross-over trial is, in
effect, two trials in one. An unpaired comparison is possible
across groups according to whether subjects are on or off
treatment, while within-patient paired comparisons are possible
across periods (before and after cross-over). For any given
patient in this trial we combine these two elements by creating
paired change scores for the corresponding times on or off
treatment (such as baseline matched to washout, 6 month
treatment matched to 6 month placebo, and 12 month treatment
matched to 12 month placebo). Mean change scores can then be
compared on an unpaired group basis according to whether
patients first received treatment or placebo. This analytical
approach generates four P values:
(1) Treatment effects represent the comparison of values on
treatment versus placebo, without regard for the order in which
each was given.
(2) Time effects capture the difference between the two
periods of the study and reflect the fact that patients may
improve or deteriorate during the course of investigation. This
entails simply comparing the overall level of measures before
cross-over (that is, when some patients are on treatment and
others on placebo) to those occurring later (that is, when
nothing should have changed except that treatment and placebo
assignments are reversed).
(3) Carry-over effects can result from an insufficient wash-out
period at time of cross-over. This simply entails comparing the
baseline and washout measures, taking specific account of
whether the patient had been on treatment or placebo prior to
the washout period. When a carry-over effect was found, we
controlled for it using the baseline and washout measures as
covariates [43]. The placebo in carry-over trials is usually
assumed to be inert, hence the test is oriented to detecting
differential carry-over effects. In this study the placebo turned
out to have its own biological activity, which at times was
similar to the treatment effect. Therefore we may have at times
failed to designate a carry-over effect as statistically significant
when both placebo (olive oil) and fish oil had carryover effects
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Table 2. Fatty acid contents of platelet membrane phospholipids (mol%) and serum lipids (mmollL)
Variable Baseline
6 Month
treatment
12 Month
treatment
Wash-out
period
6 Month
placebo
12 Month
placebo
Group 1 17.20
(0.83)
11.83
(0.76)
10.71
(0.44)
13.87
(0.85)
14.18
(1.10)
17.90
(0.94)
AA
Group 2
15.56
(1.32)
10.14
(1.30)
11.70
(1.70)
15.54
(1.85)
14.39
(0.78)
14.53
(1.14)
EPA 0.34
(0.04)
2.63
(0.20)
2.49
(0.20)
0.59
(0.07)
0.38
(0.03)
0.39
(0.04)
DHA 1.03
(0.08)
2.01
(0.16)
2.05
(0.18)
1.41
(0.12)
1.07
(0.09)
1.13
(0.09)
N3/N6 0.12
(0.01)
0.41
(0.03)
0.45
(0.04)
0.19
(0.02)
0.13
(0.01)
0.13
(0.01)
EPA/AA 0.02
(0.004)
0.26
(0.02)
0.25
(0.02)
0.04
(0.004)
0.03
(0.002)
0.02
(0.02)
DHA/AA 0.06 0.20 0.19 0.10 0.08 0.07
Triglyceride
(0.004)
1.89
(0.25)
(0.02)
1.09
(0.18)
(0.02)
1.02
(0.11)
(0.01)
1.25
(0.15)
(0.01)
1.75
(0.24)
(0.004)
1.61
(0.20)
Group 1 0.96
(0.14)
0.47
(0.08)
0.45
(0.04)
0.63
(0.10)
0.89
(0.14)
0.79
(0.12)
VLDL
Group 2
0.65
(0.15)
0.66
(0.17)
0.64
(0.14)
0.71
(0.20)
0.55
(0.18)
0.49
(0.12)
Data are mean values on or off treatment with standard errors of means in parenthesis.
of similar magnitude. This could have masked the main treat-
ment effects in some instances, and led to order effects (see
below) in others.
(4) Lastly, it is possible that the magnitude of the fish oil
effect might be significantly altered according to whether pa-
tients received treatment first or placebo first. These order
effects stem from a variety of interactions among treatment,
time, carry-over, and other unmeasured effects. Where order
effects are found, it is prudent to report both the two-period
treatment effect, and a separate pre-cross-over or first period
effect. The latter provides a parallel comparison of treatment
and placebo in the absence of any confounding order influences.
Results
Table 3. Analysis of treatment and other effects: Platelet
phospholipid fatty acid content and serum lipids
Variable
Treatment
effect
Time Order
effect effect
Carry-over
effect
P values
N31N6 <0.0001 0.12 0.30 0.02
DHA 0.0004 0.16 0.85 0.01
EPA <0.0001 0.49 0.61 0.004AA 0.0011 0.09 0.01 0.64
DHA/AA <0.0001 0.04 0.85 0.02
EPA/AA <0.0001 0.23 0.89 0.004
Triglyceride 0.04 0.10 0.44 0.71
VLDLcholestero1a 0.004 0.10 0.)3 0.54
a Pre-cross-over effects: AA, P = 0.003; VLDL, P = 0.0006
Drug compliance
An average of 14 capsules were taken daily with the range
from 11 to 15. Good compliance was also suggested by the
marked changes in platelet membrane phospholipids (Table 2).
Tabulation of outcome measures
Tables 3 and 4 provide P values for treatment, order, time
and carry-over effects for the key outcome measures. Actual
measured values [mean (SE)] are summarized in Tables 2 and 5,
combining equivalent time periods for the two groups. Where
order effects were potentially significant (P < 0.10) data are
broken down into separate groups, and a P value reported for
the parallel groups comparison of Group 1 on treatment versus
Group 2 on placebo.
Serum lipids and platelet membrane phospholipids
Among lipid measures, only serum triglyceride and VLDL
cholesterol showed a significant decrease (Table 2). Neither
LDL nor HDL cholesterols were significantly affected. Carry-
over effects were found in all platelet membrane phospholipid
fatty acids except AA (Table 3), but with or without adjustment
for carry-over influences, fish oil had a significant effect on
platelet membrane phospholipid fatty acid contents. Order
effects were found for AA and VLDL cholesterol (Table 2),
suggesting that olive oil itself affected VLDL and AA levels.
However, a parallel group comparison for VLDL and AA
confirmed the presence of treatment effects prior to cross-over.
The level of baseline proteinuria was correlated to the abso-
lute magnitude of the treatment-induced changes in triglycer-
ides and VLDL. Changes were calculated as the 10-week
treatment value versus the baseline for the corresponding
period. Correlations were —0.595 (P = 0.004) and —0.602 (P =
0.004), respectively.
Renal function
There were no significant changes in renal function measures
(Tables 4 and 5). However, the mean (SE) 24-hour urinary
protein excretion over one year of fish oil supplementation was
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Table 4. Analysis of treatment and other effects: Renal, rheologic,
and immunologic measures
Variable
Treatment
effect
Time Order
effect effect
Carry-over
effect
P values
GFR 0.48 0.25 0.05 0.70
Inverse serum 0.46 0.86 0.97 0.90
creatinine (log)
24 Hr urinary 0.22 0.92 0.50 0.92
protein (log)
Urinary IgG (log)a 0.12 0.32 0.01 0.94
wBVa 0.59 0.64 <0.0001 0.68
RCF 0.75 0.66 0.004 0.74
Bleed time' 0.01 0.02 0.06 0.80
C3 0.94 0.0002 0.90 0.44
C4 0.27 0.08 0.56 0.91
Anti-ds-DNA 0.71 0.25 0.35 0.92
a Pre-crossover effects are: GFR, F = 0.60; IgG, P = 0.47; WBV, P
= 0.59; RCF, P = 0.14; Bleed time, P = 0.58
reduced from 1424.1 mg (442.7) to 896.7 mg (352.2), P = 0.21.
When change in proteinuria was defined categorically as a
change greater than 100 mg of protein excretion per 24 hours,
nine patients showed decreased proteinuria, but three had
increased levels and nine patients exhibited no change on fish
oil (Tables 5 and 6). Urinary IgG showed an order effect (P =
0.02 for raw data, 0.03 with a log transform to correct for skew)
but no treatment effect (Table 4). GFR showed an order effect
(P = 0.05) but no treatment effect (Tables 4 and 7). Serum
creatinine remained unchanged throughout the study. For IgG
and GFR, where order effects were found, no treatment effects
were detected upon analyzing pre-cross-over data in isolation.
Clinical measures
The mean SLEDAI scores as well as mean daily steroid doses
(Table 8) were not altered by either fish oil or olive oil
supplements. There was also no significant effect on mean (SE)
blood pressure, which fell on fish oil from 101 [3] mm Hg to 96
2} mm Hg.
Rheologic measurements
Whole blood viscosity was reduced after one-year of fish oil
treatment in Group 1 patients from 4.6 (0.19) to 2.9 (0.11), but
was unaltered in Group 2 patients, 2.8 (0.11) to 2.9 (0.11). This
led to an insignificant overall treatment effect but a marked
order effect (Tables 4 and 5). Order effects (P = 0.004) were also
seen for red cell flexibility, without any fish oil effect. Fish oil
appeared more effective than the placebo in increasing bleeding
time (treatment effect P = 0.01). However, there were order
and time effects, and the pre-crossover analysis showed no
significant treatment effects (P = 0.58), rendering the results
difficult to interpret.
Immunologic markers
The individual data for C3, C4 and ds-DNA antibodies are
presented in Tables 9, 10 and 11 respectively. The C3 levels,
and to a much lesser extent C4 levels, show time effects (Table
4), suggestive of a cumulative effect from fish oil and olive oil,
where both had immunomodulatory effects. There were no
effects for ds-DNA. The analysis was repeated analyzing ds-
DNA as a categorical outcome (levels <0.20 or above 0.20),
with similar results.
Discussion
Lupus nephritis patients suffer from inflammatory and ath-
erosclerotic vascular events. The steroid and cytotoxic treat-
ment of lupus nephritis is based on clinical observations,
historically controlled, or retrospectively pooled analyses of
controlled studies [2, 4, 45]. The success and failure of these
therapies prompted us to assess fish oil dietary supplementation
since it has been noted to exert both an anti-inflammatory and
anti-atherosclerotic effect.
The present study is a single center trial. The double-blind
cross-over design reduces the inherent individual variability of
lupus nephritis by comparing each subject with himself or
herself during each dietary supplementation period. However,
the validity of certain conclusions of this study is threatened by
the fact that the 10-week washout period does not completely
prevent a carry-over effect as shown on comparing platelet
membrane phospholipid levels prior to fish oil and following
washout. Furthermore, the olive oil placebo exerts an effect on
plasma viscosity, red cell flexibility, AA, VLDL cholesterol, C3
and C4 in a direction that appears similar to fish oil. No
statistical methodology can fairly adjust for both effects con-
currently.
Olive oil was used as a placebo for fish oil because its
constituents are similar to, but in much lower concentration
than, the typical constituents of a North American diet. Indeed,
olive oil has been used almost exclusively as the placebo in fish
oil studies [14—18, 46]. All recent cross-over double-blind stud-
ies with fish oil have used olive oil as a placebo and most have
included a much shorter washout period with equal or greater
doses of fish oil. Although some of these studies addressed
issues arising from the study design, none performed and/or
reported a full analysis of the carry-over or order effects. We
presume that these studies suffered from both carry-over and
unanticipated olive oil effects as did ours [14—16, 18].
In all three lupus nephritis mouse models dietary supplemen-
tation with fish oil in the form of Menhaden oil or MaxEPA
resulted in a reduction in proteinuria and improvement in renal
morphology [25—291. The impact on human renal function has
been disappointing. Westberg and colleagues, for example,
have reported a double-blind cross-over study of MaxEPA and
placebo for six months in a mixed renal and non-renal popula-
tion of patients with systemic lupus erythematosus [461. Al-
though proteinuria was not a frequent feature of their seventeen
patients, GFRs were not significantly changed by fish oil. While
we did not assess renal morphology, proteinuria and isotope
GFR were measured with no statistically significant changes
detected. However, statistical power limitations merit mention.
Using the baseline data from the trial, and assuming that we
wished to detect and label significant a 25% treatment/placebo
difference in GFR, 15 patients per arm were needed for 80%
power. The present sample gives us about 65% power to detect
a 25% change in GFR [42]. More importantly, we observed a
37% reduction in mean levels of proteinuria, but the extreme
variability in this outcome meant that the observed difference
was compatible with the play of chance alone. Actual post hoc
power was under 20% for this outcome, underscoring the need
for a much larger sample size or more homogeneous patient
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Table 5. Mean values by period: Renal and other measures
6 Month 12 Month Wash-out
Variable Baseline treatment treatment period
6 Month
placebo
12 Month
placebo
Bleeding time mm
Group 1 5.40 5.20 5.60 6.20 6.20 6.0
(0.42) (0.33) (0.39) (0.39) (0.50) (0.53)
7.20 7.80 7.60 5.40 5.90 5.40
Group 2 (0.67) (0.60) (0.46) (0.67) (0.67) (0.57)
Red cell flexibility
Group 1 15.6 14.0 18.6 18.7 18,6 17.7
(1.28) (1.74) (1.94) (1.41) (1.69) (1.97)
18.0 16.8 16.5 16.9 8.7 16.4
Group 2 (2.09) (2.12) (1.52) (1.84) (1.63) (3.01)
Whole blood viscosity
Group 1 4.60 4.80 2.90 2.70 3.0 2.90
(0.19) (0.28) (0.09) (0.11) (0.11) (0.11)
2.80 2.60 2.90 4.30 4.00 2.90
Group 2 (0.11) (0.14) (0.11) (0.18) (0.28) (0.11)
GFR ml/min/1.73 in2
Group 1 75.5 71.4 74.7 73.3 70.9 69.2
(10.1) (9.4) (9.4) (10.5) (9.6) (9.8)
79.6 72.4 78.1 80.8 78.8 77.6
Group 2 (8.6) (10.5) (9.2) (11.7) (10.5) (10.8)
Serum creatinine iunol/ 88.52 92.14 94.48 92.29 95.62 92.57
liter (7.11) (7.71) (7.39) (6.98) (8.43) (8.62)
Urinary protein mg/24 hr 1424.14 974.95 896.71 1270.90 1162.5 1547.95
(442.67) (321.52) (352.21) (447.17) (364.20) (466.77)
Urinary IgG g/min
Group 1 9.42 7.67 6.66 8.57 15.04 8.79
(4.39) (2.11) (1.58) (2.10) (3.66) (2.61)
8.68 6.12 5.48 6.55 6.06 10.59
Group 2 (1.81) (2.13) (1.57) (2.73) (2.33) (2.73)
Data are means with standard errors of means in parenthesis.
Table 6. Urinary protein mg/24 hr
Patient 1st Year fish oil
Group 1 Baseline 6 Months
2nd Year placebo
12 Months 10 Week washout 6 Months 12 Months
1 106.00 203.00 193.00 138.00 266.00 430.00
2 190.00 39.00 94.00 105.00 1072.00 3231.00
3 461.00 72.00 61.00 121.00 107.00 122.004 7456.00 693.00 1023.00 955.00 396.00 1177.005 55.00 31.00 47.00 16.00 25.00 51.006 1465.00 1329.00 881.00 1000.00 2038.00 3254.007 148.00 42.00 165.00 100.00 22.00 45.00
8 70.00 398.00 701.00 516.00 543.00 1062.009 2501.00 5956.00 5453.00 4900.00 4359.00 294.00
10 1489.00 1726.00 204.00 106.00 406.00 80.00
11 1910.00 747.00 963.00 836.00 1177.00 2070.00
12 1802.00 1451.00 886.00 4016.00 6437.00 8137.00
13 130.00 424.00 89.00 179.00 186.00 53.00
Mean 1367.92 1008.54 827.69 999.08 1310.31 1538.92
SE 561.80 443.05 400.81 440.21 541.12 639.24
Geometric mean 490.96 352.25 325.37 323.88 432.16 452.37
Patient 1st Year placebo 2nd Year fish oil
Group 2 Baseline 6 Months 12 Months 10 Week washout 6 Months 12 Months
451.00 751.00 1180.00 1042.00 375.00 544.00
2 630.00 509.00 1576.00 663.00 473.00 238.00
3 133.00 48.00 161.00 209.00 136.00 320.00
4 45.00 22.00 90.00 46.00 61.00 65.005 43.00 11.00 34.00 33.00 19.00 37.006 262.00 541.00 380.00 369.00 98.00 432.00
7 5596.00 2697.00 3452.00 3850.00 3150.00 596.00
8 6541.00 2800.00 5609.00 5912.00 3051.00 5839.00
Mean 1712.63 922.38 1560.25 1515.50 920.38 1008.88
SE 967.07 414.44 713.75 776.72 483.90 700.81
Geometric mean 403.40 255.46 535.29 455.12 267.65 332.61
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Table 7. GFR ml/min/l.73 ,n
Patient 1St Year fish oil 2nd Year placebo
Group 1 Baseline 6 Months 12 Months 10 Week washout 6 Months 12 Months
1 71 73 72 75 69 77
2 121 111 100 94 101 91
3 121 104 104 105 100 88
4 29 23 32 28 25 33
5 137 137 141 141 122 124
6 43 40 36 35 47 45
7 68 48 86 115 94 94
8 85 80 85 68 74 74
9 36 43 37 38 27 23
10 40 35 32 30 34 33
11 85 66 66 68 69 62
12 43 69 73 41 38 28
13 102 99 107 114 121 128
Mean 75.46 71.38 74.69 73.23 70.87 69.23
SE 10.11 9.40 9.40 10.47 9.63 9.82
Patient
Group 2
1st Year placebo 2nd Year fish oil
12 Months 10 Week washout 6 Months 12 MonthsBaseline 6 Months
1 61 71 60 54 50 58
2 113 128 116 109 108 102
3 50 38 28 36 22 42
4 102 106 97 109 94 90
5 90 90 93 107 90 94
6 48 47 41 35 45 43
7 95 81 92 98 90 97
8 78 69 94 98 80 99
Mean 79.63 78.75 77.63 80.75 72.38 78.13
SE 8.64 10.45 10.91 11.71 10.52 9.16
Table 8. Prednisone dose mg/day
Patient #
Group 1
1st Year fish oil 2nd Year placebo
12 Months 10 Week washout 6 Months 12 MonthsBaseline 6 Months
1 10/5 10/0 5 5 10 5
2 10 10/0 0 0 0 5
3 10 20 10 10 10 10
4 40 20 15 15 15 15
5 5 5 5 5 5 5
6 0 0 0 0 0 0
7 20 10 10 15 15 10
8 10 10 10 15 15 10
9 10 10 10 10 15 5
10 10 10 10 10/7.5 5 7.5
11 10 10 10 10 7.5 7.5
12 10/Oa 10 10 10 10/20 10
13 10 5 5 5 5 0
.Patient #
Group 2
1st Year placebo 2nd Year fish oil
12 Months 10 Week washout 6 Months 12 MonthsBaseline 6 Months
1 10 10/0 10 10 10 10
2 10 10/0 7.5 7.5 7.5 10
3 10 10/0 10/0 10 7.5 10/5
4 0 0 0 0 0 0
5 30 10 10 10 10 10
6 15 15/12.5 12.5 12.5 12,5 10
7 10 0 10 10 10 10
8 15 20 5 5 5/7.5 5
Note: 10/0 etc. describes alternate day therapy with 10 mg taken one day alternating with 0 mg the next.
a Patient had 2 weeks of 30 mg/day then returned to 10/0
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Table 9. C3 mg/liter
Patient
Group 1
1st Year fish oil 2nd Year placebo
10 Week washout 6 Months 12 MonthsBaseline 6 Months 12 Months
1 947 807 530 498 586 495
2 583 463 421 389 364 413
3 549 346 400 426 581 560
4 1490 893 544 534 517 475
5 1080 881 630 666 666 631
6 1500 1120 797 753 877 766
7 897 737 695 651 579 558
8 712 478 494 424 487 557
9 1250 807 591 599 805 621
10 1080 793 649 589 618 595
11 1400 1200 941 833 982 866
12 724 1020 504 407 324 396
13 916 675 487 586 606 501
Mean 1010 786 591 566 615 572
su 91 70 42 38 52 36
Patient
Group 2
1st Year placebo 2nd Year fish oil
10 Week washout 6 Months 12 MonthsBaseline 6 Months 12 Months
1 777 611 530 453 451 511
2 773 621 524 486 530 650
3 650 583 395 391 313 392
4 1110 873 661 715 743 697
5 928 671 606 552 515 514
6 1020 847 638 557 524 614
7 1250 667 776 766 693 851
8 1120 816 992 872 711 861
Mean 954 711 640 599 560 636
SE 73 41 64 59 52 58
Table 10. C4 mg/liter
Patient # 1st Year fish oil 2nd Year placebo
Group 1 Baseline 6 Months 12 Months 10 Week washout 6 Months 12 Months
1 342 180 110 127 128 123
2 212 122 117 122 118 108
3 202 75 96 84 137 131
4 998 370 174 178 143 148
5 280 180 163 180 173 154
6 623 224 230 249 280 218
7 183 190 195 193 158 128
8 280 125 226 185 206 251
9 478 281 236 204 283 258
10 423 204 231 220 254 234
11 712 345 351 342 352 341
12 251 245 177 112 123 167
13 242 145 121 159 144 134
Mean 402 207 187 181 192 184
SE 68 24 19 19 21 19
Patient #
Group 2
1st Year placebo 2nd Year fish oil
Baseline 6 Months 12 Months 10 Week washout 6 Months 12 Months
1 341 233 258 210 191 217
2 177 129 125 154 129 143
3 274 184 101 124 78 123
4 422 323 294 304 347 310
5 212 246 96 67 52 86
6 489 282 255 178 215 285
7 384 173 240 267 226 297
8 321 182 262 204 155 217
Mean 328 219 204 189 174 210
SE 37 23 29 27 33 30
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Table 11. ds-DNA binding
Patient #
Group 1
1St Year fish oil 2nd Year placebo
Baseline 6 Months 12 Months 10 Week washout 6 Months 12 Months
1 <0.20 <0.20 <0.20 0.24 <0.20 <0.20
2 0.27 0.24 0.48 0.57 0,45 0.42
3 <0.20 <0.20 <0.20 <0.20 <0.20 <0.20
4 <0.20 0.28 0.48 0.40 0.22 0.21
5 <0.20 0.26 0.23 0.31 0.26 0.47
6 0.21 0.22 <0.20 <0.20 <0.20 <0.20
7 <0.20 <0.20 <0.20 <0.20 <0.20 <0.20
8 0.27 0.23 0.28 0.28 <0.20 <0.20
9 <0.20 <0.20 <0.20 0.27 <0.20 <0.20
10 <0.20 <0.20 <0.20 <0.20 <0.20 <0.20
11 <0.20 0.21 0.22 <0.20 0.22 0.22
12 0.22 0.32 0.60 0.60 0.90 0.36
13 0.35 0.35 0.46 0.59 0.60 0.75
Patient #
Group 2
1st Year placebo 2nd Year fish oil
10 Week washout 6 Months 12 MonthsBaseline 6 Months 12 Months
1 <0.20 <0.20 <0.20 <0.20 <0.20 <0.20
2 0.32 0.35 0.32 0.40 <0.20 <0.20
3 0.37 0.36 0.47 0.45 0.77 0.66
4 <0.20 <0.20 <0.20 <0.20 <0.20 <0.20
5 0.37 <0.20 <0.20 <0.20 0.31 0.25
6 <0.20 <0.20 <0.20 <0.20 <0.20 <0.20
7 0.52 0.32 <0.20 <0.20 <0.20 <0.20
8 0.25 0.42 <0.20 0.21 0.29 <0.20
A value of <0.20 represents a negative result for ds-DNA binding activity.
populations in future studies assessing the effect of fish oil on
proteinuria.
The absence of effect on clinical measures and symptoms in
our study is also compatible with Westberg's previous study
[461. The SLEDAI is a symptom scale that is well validated [33,
47] but may not be the most appropriate measure to follow in
patients with lupus nephritis as opposed to patients with pre-
dominantly extrarenal organ involvement. The scale provides a
total of 105 points for the disease activity of which only 16
represent renal involvement (Appendix 1). This is a concern
given that our patient population was relatively stable through-
out the study and did not include severely active patients.
Fish oil dietary supplementation reduced triglycerides and
VLDL cholesterol as previously noted in our dosing study [30].
Although we observed a rise in HDL cholesterol it was much
smaller than in the short-term dosing study [30] and did not
achieve significance despite our larger sample size. The reduc-
tion in triglycerides and VLDL cholesterol noted with fish oil
has been observed in patients with and without hyperlipidemia
[48—50]. Nestel et al have shown both in vivo and in vitro that
the reduction in VLDL cholesterol associated with fish oil is
due to a reduced synthesis of VLDL triglycerides and APO
protein B [51, 52]. Findings from experimental animals, per-
fused liver systems and isolated liver cell preparations consis-
tently indicate that fish oil reduces triglyceride synthesis by
substrate diversion away from triglyceride formation [53]. The
clinical significance of the lipid alterations observed in our
study remains unknown.
There were slight reductions in mean blood pressure during
the fish oil dietary supplementation, similar to those found in a
larger series of patients with essential hypertension [54, 55].
The reduction in whole blood viscosity when ingesting fish oil
has been noted by others and in our short-term dosing study
[30, 55—57]. Neither fish oil nor olive oil led to a significant
change in red cell flexibility, although fish oil did alter red cell
flexibility in our previous short-term study [30]. A reduction in
whole blood viscosity could potentially contribute to a decrease
in glomerular capillary permeability and the resultant protein-
uria [58].
In sum, this two-year double-blind cross-over study of stable
lupus nephritis patients and Westberg's six-month double-blind
cross-over study of lupus patients with mild nephritis have
generated similar results [46]. In both studies GFR and clinical
responses measured by different scales were not affected by fish
oil or placebo. Moreover, in our lupus nephritis population the
reduction in proteinuria during fish oil dietary supplementation
did not achieve significance, but this may be attributable to
variability in proteinuria levels and resultant low statistical
power. Measures of dyslipidemia, specifically serum triglycer-
ides and VLDL cholesterol, were significantly lowered with fish
oil treatment. The modest improvements observed during fish
oil dietary supplementation compared with placebo do not
support a recommendation that fish oil dietary supplementation
be considered a routine treatment for lupus nephritis patients.
Given the placebo and carry-over effects noted in our analysis,
we do recommend that any future cross-over trials assessing the
effect of fish oil on dyslipidemias or renal function be performed
without olive oil as a placebo and with a longer washout period.
Better yet, we would urge that, where possible, cross-over
designs be avoided given the complexity of the effects as shown
here and the risk of similar problems in similar studies.
Lastly, we raise two general cautions about all studies of fish
oil to date. First, the above-noted differential carry-over effects
are important confounders in any study using a cross-over
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design. Second, the general adoption of olive oil as a placebo is
a potential source of type II error in both cross-over and parallel
group designs. Studies showing beneficial effects of fish oil
relative to olive oil placebo may therefore be underestimating
the achievable benefits. Furthermore, in studies where fish oil is
not found to be beneficial, re-examination of the findings or
further study with a more physiologically inert placebo may be
appropriate.
Acknowledgments
We would like to thank the Kidney Foundation of Canada for
supporting the project, the R.P. Scherer (Canada), Windsor, Ontario for
providing both fish oil and placebo capsules. We would also like to
thank Sharon Clark for secretarial assistance, Esmé French for clinical
coordination and Teresita Daite, Frances Andrus and Sandi Kleinsiver
for technical assistance. This work was presented in part at the Third
International SLE Symposium (London, U.K., April 1992).
Reprint requests to Dr. W.F. Clark, Department of Medicine, Victo-
ria Hospital, 375 South Street, London, Ontario, Canada N6A 4G5.
References
1. DuBols EL, WIER1cH0wIEcKI M, Cox MB, WEINERJM: Duration
and death in systemic lupus erythematosus. An analysis of 249
cases. JAMA 227:1399—1402, 1974
2. ALBERT DA, HADLER NM, ROPES MW: Does corticosteroid ther-
apy affect the survival of patients with systemic lupus erythemato-
sus? Arthr Rheum 22:945—953, 1979
3. GINZLER EM, DIAMOND HS, WEINER M, SCHLESINGER M, FRIES
JF, WA5NER C, MEDSGER TA JR, ZIEGLER G, KLIPPEL JH,
HADLER NM, ALBERT DA, HESS EV, SPENCER-GREEN G, Gx'-
ZEL A, WORTH D, HAHN BH, BARNETF EV: A multicenter study of
outcome in Systemic lupus erythematosus. 1. Entry variables as
predicters of prognosis. Arthr Rheum 25:601—611, 1982
4. BALOW JE, AUSTIN III HA, TS0K0s GC, ANTONOBYCH TT,
STEINBERG AD, KLIPPEL JH: Lupus nephritis (NIH conference).
Ann mt Med 106:79—94, 1987
5. PONTICELLI C, ZUCCHELLI P, Moor.n G, CAGNALI L, BONFI 0,
PASQUALI S: Long-term prognosis of diffuse lupus nephritis. Clin
Nephrol 28:263—271, 1987
6. UROWITZ MB, BOOKMAN AAM, KOEHLER BE, GORDON DA,
SMYTHE HA, ORGYZLO MA: The bimodal mortality of systemic
lupus erythematosus. Am J Med 60:221—225, 1976
7. KARSH J, KLIPPEL JH, BALOW JE, DECKER JL: Mortality in lupus
nephritis. Arthr Rheum 22:764—769, 1979
8. CORREIA P, CAMERON JS, LIAN JD, HICKS J, OGG CS, WILLIAMS
DG, CHANTLER C, HAYCOCK DG: Why do patient with lupus
nephritis die? Brit MedJ 290:126—131, 1985
9. HOSENPUD JD, MONTANARO A, HART MV, HAINES JE, SPECHT
HD, BENNETT RM, KLOSTER FE: Myocardial perfusion abnormal-
ities in asymptomatic patients with systemic lupus erythematosus.
Am J Med 77:286—292, 1984
10. SIM0POULOs AP: Omega-3 fatty acids in health and disease and in
growth and development. Am J Cliii Nutr 54:438—463, 1991
11. DYERBERG J, BANG HO: Haemostatic function and platelet poly-
unsaturated fatty acids in Eskimos. Lancet 11:433—435, 1979
12. NEEDLEMAN P, RAZ A, MINKES MS, FERRENDELLI JA, SPRECHER
H: Triene prostaglandins: Prostacycin and thromboxane biosyn-
thesis and unique biological properties. Proc Nat! Acad Sci USA
76:944—948, 1979
13. LEE TH, MENCIA-HUERTER JM, SHIH C, CORREY EJ, LEwis RA,
AUSTEN KF: Effects of exogenous arachidonic, eicosapentaenoic
and docosahexaenoic acids on the generation of 5-lipoxygenase
pathway products by ionophore activated human neutrophils. J
Clin Invest 74:1922—1933, 1984
14. KREMER JM, JUBIZ W, MICHALEK A, RYNES R, BARTHOLOMEW
LE, BIGAOUETTE J: Fish-oil fatty acid supplementation in active
rheumatoid arthritis. Ann Intern Med 106:497—503, 1987
15. KREMERJM, LAWRENCE DA, JUBIZ W, DI GIAc0M0 R, RYNES R,
BARTHOLOMEW LE, SHERMAN M: Dietary fish oil and olive oil
supplementation in patients with rheumatoid arthritis. Art hr Rheum
33:810—820, 1991)
16. BITTINER SB, TUCKER WFG, CARTWRIGHT I, BLEEHEN SS: A
double-blind, randomized, placebo-controlled trial of fish oil in
psoriasis. Lancet 1:378—380, 1988
17. BJORNEBOE A, SMITH AK, BJORNEBOE GAA, THUNE P0, DREVON
CA: Effect of dietary supplementation with n-3 fatty acids on
clinical manifestation of psoriasis. Br J Dermatol 118:77—83, 1988
18. STENSON WF, CORT D, RODGERS J, BURAKOFF R, DE-SCHRYVER-
KECSKEMETI K, GRAMLICH TL, BECKEN W: Dietary supplemen-
tation with fish oil in ulcerative colitis. Ann Intern Med 116:609—
614, 1992
19. DYERBERG J, BANG HO, HJORNE N: Fatty acid composition of the
plasma lipids in Greenland Eskimos. Am J Clin Nutr 28:958—960,
1975
20. BANG HO, DYERBERG J, HJORNE N: The composition of food
consumed by Greenland Eskimos. Acta Med Scand 200:69—73,
1976
21. KROMHOUT D, BOSSCHIETER EB, COULANDER CL: The inverse
relation between fish consumption and 20 year mortality from
coronary heart disease. N Engi J Med 312:1205—1209, 1985
22. DYERBERG J: Linolenate-derived polyunsaturated fatty acids and
prevention of atherosclerosis. Nutr Rev 44:125—134, 1986
23. HEROLD PM, KINSELLA JE: Fish oil consumption and decreased
risk of cardiovascular disease: A comparison of findings from
animal and human feeding trials. Am J Clin Nutr 43:566—598, 1986
24. VON SCHACKY C: Prophylaxis of atherosclerosis with marine Ome-
ga-3 fatty acids. Ann Intern Med 107:890—899, 1987
25. PRICKETT JD, ROBINSON DR, STEINBERG AD: Dietary enrichment
with the polyunsaturated fatty acid eicosapentenoic acid prevents
proteinuria and prolongs survival in NZB x NZW/F1 mice. J Clin
Invest 68:556—559, 1981
26. PRICKETT JD, ROBINSoN DR, STEINBERG AD: Effects of dietary
enrichment with eicosapentaenoic acid upon autoimmune nephritis
in female NZB x NZW/F1 mice. ArthrRheum 26:133—139, 1983
27. ROBINsoN DR, PRICKETT JD, MAKOUL GT, STEINBERG AD,
CALVIN RB: Dietary fish oil reduces progression of established
renal disease in (NZB x NZW) F1 mice and delays renal disease in
BXSB, and MRL/l strains. Art hr Rheum 29:539—546, 1986
28. KELLEY VE, FERRETTI A, Izui S, STROM TB: A fish oil diet rich in
eicosapentaenoic acid reduces cyclooxygenase metabolites, and
suppresses lupus in MRL-lpr mice. Jlmmunol 134:1914—1919, 1985
29. WESTBERG 0, TARKOWSKI A, SVALANDER C: Effect of eicosapen-
taenoic acid-rich Menhaden oil and MaxEPA on the autoimmune
disease of MRL/lpr mice. mt Arch Allergy App! Immunol 88:454—
461, 1989
30. CLARK WF, PARBTANI A, HUFF MW, REID B, HOLUB BJ,
FALARDEAU P: Omega-3 fatty acid dietary supplementation in
systemic lupus erythematosus. Kidney Int 36:653—660, 1989
31. TAN EM, COHEN AS, FRIES JF, MA5I AT, MCSI-IANE DJ, ROTH-
FIELD NF, SCHALLER JO, TALAL N, WINCHESTER Ri: The 1982
revised criteria for the classification of systemic lupus erythemato-
sus. Arthr Rheum 25:1271—1272, 1982
32. WooDs JR, WILLIAMS JO, TAVEL M: The two-period crossover
design in medical research. Ann Intern Med 110:560—566, 1989
33. COMMITTEEON PROGNOSIS STUDIEs: Progress studies in SLE: An
activity index. Arthr Rheum (Suppl 4):S29—S93, 1986
34. BLIGH WG, DYER WJ: A rapid method of total lipid extraction and
purification. Can J Biochem Physio! 37:911—919, 1959
35. FOLCH J, LEES M, SLOAN-STANLEY GH: A simple method for the
isolation and purification of total lipids from animal tissues. J Biol
Chem 226:497—509, 1957
36. HOLUB BJ, SKEAFF CM: Nutritional regulation of cellular phos-
photidyl inositol, in Methods in Enzymology-Cellular Regulators:
Calcium and Lipids, edited by PM CONN, AR MEANS, New York
Academic Press, 1987, pp 234—244
37. RUSSELL CD, BIscnon-i P0, KONTZEN FN, ROWELL KL, YESTER
MV, LLOYD KL: Measurement of glomerular filtration rate: Single
injectionplasma clearance method without urine collection. J NucI
Med 26:1243—1247, 1985
38. WARNICK OR, BENDER5ON J, ALBERS JJ: Dextran sulphate Mg2
Clark et al: Fish oil in lupus nephritis 85
precipitation procedure for quantitation of high density lipoprotein
cholesterol. Gun Chem 28:1378—1388, 1982
39. FRIEDWALD WT, LEVY RI, FREDRICKSON DS: Estimation of the
concentration of low density lipoprotein cholesterol in plasma
without the use of the preparation ultracentrifuge. Gun Chem
18:499—502, 1972
40. SIRS JA: Automatic recording of the rate of packing of erythrocytes
in blood by a centrifuge. Physiol Med Biol 15:9—14, 1970
41. WRIGHT DJ, JENKINS DE: Simplified method for estimations of
serum and plasma viscosity in multiple myeloma and related
disorders. Blood 36:516—522, 1970
42. COHEN J: Statistical Power Analysis for the Behavioural Sciences.
New Jersey, Lawrence Erlbaum Associates, 1988
43. ARMITAGE P, BERRY G: Statistical Methods in Medical Research.
Oxford, Blackwell Scientific Publications, 1987, pp 222—226
44. FLEISS JL: The Design and Analysis of Clinical Experiments. New
York, John Wiley & Sons, 1986, pp 263—305
45. FELSON DT, ANDERSON J: Evidence for the superiority of immu-
nosuppressive drugs and prednisone over prednisone alone in lupus
nephritis. Results of a pooled analysis. N Engi J Med 311:1528—
1533, 1984
46. WESTBERG G, TARKOWSKI A: Effect of Maxepa in patients with
SLE. A double-blind crossover study. ScandJRheum 19:137—143,
1990
47. LIANG MH, SOCHER SA, LARSON MG, SHORE AH: Reliability and
validity of 6 systems for the clinical assessment of disease activity
in SLE. Arthr Rheum 32:407—418, 1989
48. BRONSGEEST-SCHOUTE HC, VANGENT CM, LUTEN JB, RUITER A:
The effect of various intakes of n-3 fatty acids on the blood lipid
composition in healthy human subjects. Am J Clin Nutr 34:1752—
1757, 1981
49. PHILLIPSON B, ROTHROCK DW, CONNOR WE, HARRIS WS, ILL-
INGSWORTH DR: Reduction of plasma lipids, lipoproteins, and
apoproteins by dietary fish oils in patients with hypertriglyceri-
demia. NEnglJMed3l2:l210—1216, 1985
50. C0BIAc L, CLIFTON PM, ABBEY M, BELLING GB, NESTEL PJ:
Lipid, lipoprotein, and hemostatic effects of fish vs. fish oil n-3 fatty
acids in mildly hyperlipidemic males. Am J Clin Nutr 53:1210—1216,
1991
51. NESTEL PJ, CONNOR WE, REARDON MF, CONNOR S, WONG 5,
BOSTON R: Suppression by diets rich in fish oil of very lOw density
lipoprotein production in man. J Clin Invest 74:82—89, 1984
52. WONG SH, REARDON MF, NESTEL PJ: Reduced triglyceride for-
mation from long chain polyenoic fatty acids in rat hepatocytes.
Metabolism 34:900—905, 1985
53. NESTEL PJ: Effects of n-3 fatty acids on lipid metabolism. Ann Rev
Nutr 10:149—167, 1990
54. BONAA K: Epidemiological and intervention studies on the effect of
marine polyunsaturated fatty acids on blood pressure. Jlntern Med
225(SI): 105—110, 1989
55. BONAA KH, BJERVE KS, STRAUME B, GRAM IT, THELLE D: Effect
of eicosapentaenoic and docosahexaenoic acids of blood pressure
in hypertension. A population-based interaction trial from the
Tromso Study. N Engi J Med 332:795—801, 1990
56. POpp-SNIrnER5 C, SCHOUTEN JA, DE JONG AP, VAN DER VEEN
EA. Effects of dietary cod liver oil on the lipid composition of
erythrocyte membranes. Scand J Clin Lab Invest 44:39—46, 1984
57. CARTWRIGHT IJ, POCKLEY AG, GALLOWAY JH, GREAVES M,
PRESTEN FE: The effects of dietary omega-3 polyunsaturated fatty
acids on erythrocyte membrane phospholipids, erythrocyte de-
formability and blood viscosity in healthy volunteers. Atheroscle-
rosis 55:267—281, 1985
58. SIMPSON LO: A hypothesis proposing increased blood viscosity as
a cause of proteinuria and lincreased vascular permeability.
Nephron 3 1:89-95, 1982
86 Clark et a!: Fish oil in lupus nephritis
Appendix. SLEDAI-DATA COLLECTION SHEET
(Enter weight in SLEDAI score column if descriptor present at the time of the visit or in the preceding 10 days)
Total
SLEDAI
Score: _______________
8
8
8
8
8
8
4
Weight
SLEDAI
Score Descriptor Definition
Seizure Recent onset. Exclude metabolic, infectious or drug causes.
Psychosis Altered ability to function in normal activity due to severe disturbance in the perception
of reality. Includes: hallucinations, incoherence, marked loose associations,
impoverished thought content, marked illogical thinking, bizarre disorganized or
catatonic behavior. Exclude presence of uremia and offending drugs.
8 Organic brain
syndrome
Altered mental function with impaired orientation, memory or other intellectual function
with rapid onset, fluctuating clinical features. Such as any of the following: (a)
clouding of consciousness with reduced capacity to focus and inability to sustain
attention to environment. Plus at least 2 of (b) of perceptual disturbance; incoherent
speech; insomnia or daytime drowsiness; increased or decreased psychomotor
activity. (Exclude metabolic, infectious, drugs caused).
8 Visual Retinal changes of SLE; any of cytoid bodies, retinal hemorrhages, serous exudate or
hemorrhages in the choroid, optic neuritis. (Not due to hypertension or drugs or
infection).
-
Cranial nerve New onset of sensory or motor neuropathy involving the cranial nerve.
Lupus headache Severe, persistent headache, may be migrainous, but must be non-responsive to
narcotic analgesia.
CVA New syndrome. Exclude arteriosclerosis.
Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages,
biopsy or angiogram proof of vasculitis.
Arthritis More than 2 joints with pain and signs of inflammation (i.e. tenderness, swelling or
effusion).
4 Myositis Proximal muscle aching/weakness, associated with elevated CPK/aldolase or EMG
changes or a biopsy showing myositis.
Casts Heme granular or RBC.
Hematuria >5 RBC/hpf. Excluding other causes (stone, infection)
Proteinuria >0.5 g/24 hours. New onset or recent increase of more than 0.5 g/24 hours.
Pyuria >5 WBC/hpf. Exclude infection.
New rash New onset or recurrence of inflammatory type rash.
Alopecia New onset or recurrent. An abnormal patch of diffuse loss of hair.
Mucous membrane New onset or recurrence of oral or nasal ulcerations.
Pleurisy Pleuritic chest pain with pleural rub or effusion or pleural thickening.
Pericarditis Pericardial pain with at least one of the following: rub, effusion, EKG, echo
confirmation.
Low complement Decreased any of CH5O, C3, C4. Below the lower limit of normal for lab.
Increased DNA
binding
>25% binding by Farr assay. Above normal range of lab value (eg. 25%)
Fever >38 C After exclusion of infection.
Thrombocytopenia <100,000 platelets.
Leukopenia WBC < 000 (not due to drugs)
4
4
4
4
2
2
2
2
2
2
2
